Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Partow Kebriaei

Showing results (141-150 of 346) with videos related to

Pageof 35
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcomeYago Nieto, Uday Popat, Paolo Anderlini, et al.
American Journal of Hematology|May 13, 2026
Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell TransplantGeorge L Chen, Roland Bassett, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
Haematologica|August 20, 2016
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaBetül Oran, Jeff L Jorgensen, David Marin, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Haematologica|September 24, 2013
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donorsDavid I Marks, Kwang Ahn Woo, Xiaobo Zhong, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Pageof 35

Showing results (141-150 of 346) with videos related to

Sort By:
Pageof 35
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcomeYago Nieto, Uday Popat, Paolo Anderlini, et al.
American Journal of Hematology|May 13, 2026
Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell TransplantGeorge L Chen, Roland Bassett, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
Haematologica|August 20, 2016
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaBetül Oran, Jeff L Jorgensen, David Marin, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Haematologica|September 24, 2013
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donorsDavid I Marks, Kwang Ahn Woo, Xiaobo Zhong, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeOren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Pageof 35